🇺🇸 FDA

P1 · Therapeutic area intelligence

Rare disease patent intelligence

Orphan and rare disease pharmaceutical patents with exclusivity and formulation coverage.

Patents
26

Quick answer

26 US pharmaceutical patents in our index match Rare disease title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12228582

    Method and apparatus for testing near infrared-photoimmunotherapy treatment

    The United States of America as Represented By The Secretary of the Department of Health and Human · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12168802

    Methods of diagnosing and treating CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE), a newly identified orphan disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12076316

    Levorphanol prodrugs and processes for making and using them

    Zevra Therapeutics, Inc. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12012384

    Dextrorphan prodrugs and processes for making and using them

    Zevra Therapeutics, Inc. · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11786539

    Aminoglycoside derivatives and uses thereof in treating genetic disorders

    ELOXX PHARMACEUTICALS LTD. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11613551

    Aminoglycoside derivatives and uses thereof in treating genetic disorders

    ELOXX PHARMACEUTICALS LTD. · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11548953

    Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

    The Regents of the University of California · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11306115

    Aminoglycoside derivatives and uses thereof in treating genetic disorders

    ELOXX PHARMACEUTICALS LTD. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11046670

    Piperazinyl norbenzomorphan compounds and methods for using the same

    The Board of Regents of the University of Texas System · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11021523

    Cyanobacteriochromes active in the far-red to near-infrared

    The Regents of the University of California · Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11013803

    Near infrared photoimmunotherapy (NIR-PIT) of suppressor cells to treat cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10973869

    Methods of treating cardiomyopathy associated with genetic disorders

    Compass Therapeutics LLC · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10899785

    Aminoglycoside derivatives and uses thereof in treating genetic disorders

    ELOXX PHARMACEUTICALS LTD. · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10786520

    Aminoglycoside derivatives and uses thereof in treating genetic disorders

    ELOXX PHARMACEUTICALS LTD. · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10689646

    Treatment of genetic disorders associated with DNA repeat instability

    BIOMARIN TECHNOLOGIES B.V. · Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10201282

    Genetically encoded infrared fluorescent protease reporters

    The Regents of the University of California · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10175170

    Metal coating of rare earth nano-phosphors and uses thereof

    The Regents of the University of California · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10093629

    Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9938350

    Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

    The Regents of the University of California · Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9890379

    Treatment of genetic disorders associated with DNA repeat instability

    BIOMARIN TECHNOLOGIES B.V. · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9815870

    Monomeric and bright infrared fluorescent proteins

    The Regents of the University of California · Granted Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9242014

    Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

    The Regents of the University of California · Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 6699482

    Leptospira rare outer membrane proteins

    The Regents of the University of California · Granted Tue Mar 02 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  24. US 6677439

    Methods for isolating T. pallidum rare outer membrane proteins

    The Regents of the University of California · Granted Tue Jan 13 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  25. US 6207413

    Nucleic acids encoding novel orphan cytokine receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 27 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  26. US 6060276

    Nucleic acids encoding novel orphan cytokine receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 09 2000 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many Rare disease patents are indexed?

26 patents match our Rare disease classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.